Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Arvinas stock
Learn how to easily invest in Arvinas stock.
Arvinas Inc is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Arvinas employs 280 staff and has a trailing 12-month revenue of around $91.1 million.
How to buy shares in Arvinas
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARVN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Arvinas stock price (NASDAQ: ARVN)Use our graph to track the performance of ARVN stocks over time.
Arvinas shares at a glance
|Latest market close||$42.06|
|52-week range||$34.90 - $97.33|
|50-day moving average||$48.93|
|200-day moving average||$57.47|
|Wall St. target price||$91.30|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-4.18|
Buy Arvinas shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arvinas stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arvinas price performance over time
|1 week (2022-09-19)||-9.84%|
|1 month (2022-08-26)||-4.88%|
|3 months (2022-06-24)||-8.17%|
|6 months (2022-03-22)||N/A|
|1 year (2021-09-24)||-52.53%|
|2 years (2020-09-25)||72.24%|
|3 years (2019-09-26)||78.67%|
|5 years (2017-09-22)||N/A|
|Revenue TTM||$91.1 million|
|Gross profit TTM||$46.7 million|
|Return on assets TTM||-14.02%|
|Return on equity TTM||-37.19%|
|Market capitalisation||$2.2 billion|
TTM: trailing 12 months
Arvinas share dividends
We're not expecting Arvinas to pay a dividend over the next 12 months.
Arvinas share price volatility
Over the last 12 months, Arvinas's shares have ranged in value from as little as $34.9 up to $97.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 2.0601. This would suggest that Arvinas's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arvinas, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc. , Genentech, Inc. , F. Hoffman-La Roche Ltd.
Arvinas in the news
Arvinas to Present at Bank of America Securities Precision Oncology Conference
hC Bioscience Appoints Brad Margus to its Board of Directors
hC Bioscience Appoints Brad Margus to its Board of Directors
Frequently asked questionsWhat percentage of Arvinas is owned by insiders or institutions?
Currently 11.51% of Arvinas shares are held by insiders and 97.024% by institutions. How many people work for Arvinas?
Latest data suggests 280 work at Arvinas. When does the fiscal year end for Arvinas?
Arvinas's fiscal year ends in December. Where is Arvinas based?
Arvinas's address is: 5 Science Park, New Haven, CT, United States, 06511 What is Arvinas's ISIN number?
Arvinas's international securities identification number is: US04335A1051 What is Arvinas's CUSIP number?
Arvinas's Committee on Uniform Securities Identification Procedures number is: 04335A105
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert